Zenas Biopharma Inc stock is traded at $25.93, with a volume of 822,606. It is down -8.89% in the last 24 hours and down -6.83% over the past month. Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Previous Close:
$28.46
Open:
$28.10
24h Volume:
822,606
Relative Volume:
1.63
Market Cap:
$1.69B
Revenue:
$10.00M
Net Income/Loss:
-$425.15M
P/E Ratio:
-
EPS:
-$9.10
Net Cash Flow:
-$210.48M
1W Performance:
-9.84%
1M Performance:
-6.83%
6M Performance:
+24.90%
1Y Performance:
-15.07%
1-Day Range:
$25.79$28.49
1-Week Range:
$25.79$29.91
52-Week Range:
$13.50$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma IncSector
HealthcareIndustry
BiotechnologyPhone
857-271-2954Address
852 WINTER STREET, SUITE 250, WALTHAM, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS